Clene to Host Expert Perspectives Webinar on Cellular Energetic Failure and the Unmet Medical Needs in ALS and MS
June 30, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Added to Membership of Russell 2000® Index
June 28, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, June 28, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene to Present at the Raymond James Human Health Innovation Conference
June 15, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, June 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placement
May 24, 2021 08:00 ET
|
Clene Inc.
SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Appoints David J. Matlin as Chairman of the Board
May 19, 2021 09:00 ET
|
Clene Inc.
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging
May 17, 2021 07:00 ET
|
Clene Inc.
International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease Clene anticipates the...
Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 Annual Meeting
May 12, 2021 09:00 ET
|
Clene Inc.
Preliminary blinded efficacy data suggest CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients Patients demonstrated improvement from baseline, as compared...
Clene Reports First Quarter 2021 Operating and Financial Highlights
May 11, 2021 07:00 ET
|
Clene Inc.
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients ...
Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Technology
April 30, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, April 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Reports Full Year 2020 Operating and Financial Highlights
March 29, 2021 07:00 ET
|
Clene Inc.
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics Topline data from a Phase 2 ALS trial and two Phase 2 target engagement studies in MS and Parkinson’s...